In a Phase I clinical trial of a peptide inhibitor of TRPV6 activity two patients with advanced pancreatic cancers showed tumour reduction (one by -27% by RECIST criteria) with one patient showing 55% decrease in the validated pancreatic cancer biomarker CA19-9 103. Here, TRPV6 is linked to familial pancreatic carcinoma.